Supporting development of mRNA-based therapies by addressing large scale purification challenges

The field of mRNA-based therapies is rapidly evolving. The potential of these therapies has been demonstrated in various fields such as cancer vaccines, tumor immunotherapy and more recently, gene editing and vaccine development. Although the potential of mRNA in therapies seems to be endless, obtaining larger quantities of synthetic mRNA for clinical treatment remains a challenge. The current available methods for mRNA purification are becoming a bottleneck in large-scale manufacturing.

Affinity chromatography, a highly scalable method, has earned its credits in the development of biologics such as the use of Protein A for the purification of therapeutic antibodies and more recently, anti-AAV resins in gene therapy workflows. An effective affinity purification step can help to simplify biomolecule downstream processing, reduce the number of purification steps, and reduce the overall cost of goods in bio-therapeutic manufacturing. To support the development of mRNA-based therapies, we have developed a new affinity resin for the purification and isolation of mRNA from in vitro transcription (IVT) manufacturing processes. This webinar will provide an overview on how this resin can help to maximize efficiency and simplify the mRNA purification process.

Kelly Flook

Senior Product Manager, Purification, Bioproduction Division, Thermofisher scientific

Kelly Flook is Senior Product Manager for Purification products within the Bioproduction Division at Thermo Fisher Scientific. Kelly has a Ph.D in Polymer and Analytical Chemistry from the University of Durham, UK. During her 15 years at Thermo Fisher, Kelly has gained extensive experience in product development across all scales of chromatography and related biological workflows. Kelly has a strong expertise in bead technology and bio-separations. Drawing from a diverse technical background, in her current role Kelly is responsible for new product development and commercialization of solutions across the downstream workflow.

Watch now

SPEAKERS

Kelly Flook

Senior Product Manager, Purification, Bioproduction Division, Thermofisher scientific

You might also like

Scalable chromatographic strategies for mRNA and saRNA purification from IVT

Tomas Kostelec

29 February

Watch

Quality by design in mRNA manufacturing: at-line monitoring coupled with DOE for higher IVT yield and efficiency of purification

Rok Sekirnik

3 December

Watch

Process optimization of mRNA purification for vaccines and therapeutic applications

Chantelle Gaskin

13 June

Watch

Commercial-scale manufacture of lentivirus for ex vivo and in vivo therapies

Rachel Legmann, Michelle Yen Tran

28 March

Watch

Large-scale manufacturing of allogeneic stem cell-derived NK cell therapies

Monica Raimo, Jan Spanholtz

6 August

Watch